D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Vertex Pharmaceuticals scored a major win with the EU approval of ALYFTREK, expanding its cystic fibrosis treatment access in ...

Most children with CF treated at a San Francisco CF clinic did not receive CF liver disease screening in accordance with current guidelines.

ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR ...

Without Medicaid, the level of care that Walter and other children like him require on an ongoing basis would be inaccessible to families. Yet that is what members of Congress are currently ...

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.

Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive ...

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

John William Crane was born on March 21, 1971, to Don and Libby Crane, and at the age of two years diagnosed with CF and ...

Vertex Pharmaceuticals secured EU approval for ALYFTREK, a next-gen cystic fibrosis therapy boasting a better efficacy ...

Middlesbrough Under 13s Rugby Team have launched a charity walk in memory of Mylo Capilla and have raised thousands ...

Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...